Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherTheranostics
Open Access

Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients

Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts
Journal of Nuclear Medicine December 2020, jnumed.120.255679; DOI: https://doi.org/10.2967/jnumed.120.255679
Matthias D'Huyvetter
1 Precirix NV/SA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens De Vos
1 Precirix NV/SA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicky Caveliers
2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilse Vaneycken
3 Nuclear Medicine Department, UZ Brussel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Heemskerk
3 Nuclear Medicine Department, UZ Brussel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois P. Duhoux
4 Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, and Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christel Fontaine
5 Department of Medical Oncology, UZ Brussel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marian Vanhoeij
6 Department of Oncological Surgery, UZ Brussel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert D. Windhorst
7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank van der Aa
7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Harry Hendrikse
7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jos L.E. Eersels
2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendrik Everaert
3 Nuclear Medicine Department, UZ Brussel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieterjan Gykiere
3 Nuclear Medicine Department, UZ Brussel;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Devoogdt
1 Precirix NV/SA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geert Raes
1 Precirix NV/SA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony Lahoutte
1 Precirix NV/SA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marleen Keyaerts
2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.120.255679
DOI 
https://doi.org/10.2967/jnumed.120.255679
PubMed 
33277400

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online December 4, 2020.

Article Versions

  • You are currently viewing a previous version of this article (December 4, 2020 - 12:52).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Matthias D'Huyvetter1,
  2. Jens De Vos1,
  3. Vicky Caveliers2,
  4. Ilse Vaneycken3,
  5. Johannes Heemskerk3,
  6. Francois P. Duhoux4,
  7. Christel Fontaine5,
  8. Marian Vanhoeij6,
  9. Albert D. Windhorst7,
  10. Frank van der Aa7,
  11. N. Harry Hendrikse7,
  12. Jos L.E. Eersels2,
  13. Hendrik Everaert3,
  14. Pieterjan Gykiere3,
  15. Nick Devoogdt1,
  16. Geert Raes1,
  17. Tony Lahoutte1 and
  18. Marleen Keyaerts2
  1. 1 Precirix NV/SA;
  2. 2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Belgium;
  3. 3 Nuclear Medicine Department, UZ Brussel;
  4. 4 Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, and Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain;
  5. 5 Department of Medical Oncology, UZ Brussel;
  6. 6 Department of Oncological Surgery, UZ Brussel;
  7. 7 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology & Nuclear Medicine
  1. For correspondence or reprints contact: Marleen Keyaerts, In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels 1090, Belgium. E-mail: marleen.keyaerts@vub.be

Statistics from Altmetric.com

Cited By...

  • 82 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance
    Taniya Saha, Kiven Erique Lukong
    Frontiers in Oncology 2022 12
  • GPC3-targeted immunoPET imaging of hepatocellular carcinomas
    Shuxian An, Di Zhang, You Zhang, Cheng Wang, Liang Shi, Weijun Wei, Gang Huang, Jianjun Liu
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 8
  • ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053
    Cheng Wang, Yumei Chen, Yun Nan Hou, Qiufang Liu, Di Zhang, Haitao Zhao, You Zhang, Shuxian An, Lianghua Li, Jian Hou, Gang Huang, Jianjun Liu, Yong Juan Zhao, Weijun Wei
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 9
  • Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
    Haonan Li, Qiang Luo, Hu Zhang, Xuelei Ma, Zhongwei Gu, Qiyong Gong, Kui Luo
    Chemical Society Reviews 2023 52 1
  • Engineering nanobodies for next-generation molecular imaging
    Erpeng Yang, Qiufang Liu, Gang Huang, Jianjun Liu, Weijun Wei
    Drug Discovery Today 2022 27 6
  • Applications of nanobodies in brain diseases
    Fang Zheng, Yucheng Pang, Luyao Li, Yuxing Pang, Jiaxin Zhang, Xinyi Wang, Geert Raes
    Frontiers in Immunology 2022 13
  • Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
    Cristina Barca, Christoph Griessinger, Andreas Faust, Dominic Depke, Markus Essler, Albert Windhorst, Nick Devoogdt, Kevin Brindle, Michael Schäfers, Bastian Zinnhardt, Andreas Jacobs
    Pharmaceuticals 2021 15 1
  • Single-Domain Antibody Theranostics on the Horizon
    Weijun Wei, Muhsin H. Younis, Xiaoli Lan, Jianjun Liu, Weibo Cai
    Journal of Nuclear Medicine 2022 63 10
  • Nanobodies as molecular imaging probes
    Sarah Barakat, Melike Berksöz, Pegah Zahedimaram, Sofia Piepoli, Batu Erman
    Free Radical Biology and Medicine 2022 182
  • High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers
    Xue Qin, Xiaoyi Guo, Tianyu Liu, Liqiang Li, Nina Zhou, Xiaopan Ma, Xiangxi Meng, Jiayue Liu, Hua Zhu, Bing Jia, Zhi Yang
    European Journal of Nuclear Medicine and Molecular Imaging 2023 50 2

Article usage

Article usage: December 2020 to April 2025

AbstractFullPdf
Dec 20205960253
Jan 20213050123
Feb 2021186078
Mar 2021170067
Apr 2021165076
May 2021131057
Jun 2021138076
Jul 202125313112
Aug 202187749112
Sep 202175942125
Oct 202176853109
Nov 20214732674
Dec 20215362153
Jan 20226235469
Feb 20227541488
Mar 2022108406137
Apr 202298259116
May 202286261113
Jun 20227131772
Jul 20225937935
Aug 20225436049
Sep 20227939275
Oct 20227028562
Nov 202215316860
Dec 20229346164
Jan 20236445665
Feb 20235940363
Mar 20236344470
Apr 20234533847
May 202375275114
Jun 20235331170
Jul 20239126777
Aug 20234937455
Sep 20237734679
Oct 20236725676
Nov 20238535671
Dec 20234414582
Jan 20247424659
Feb 20247528742
Mar 20246919699
Apr 20246514778
May 20246011267
Jun 2024508851
Jul 20244521391
Aug 20243818286
Sep 20243812372
Oct 20245911663
Nov 20243512361
Dec 20242813061
Jan 20252810370
Feb 20253518386
Mar 20253414974
Apr 202555211125
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte, Marleen Keyaerts
Journal of Nuclear Medicine Dec 2020, jnumed.120.255679; DOI: 10.2967/jnumed.120.255679

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients
Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte, Marleen Keyaerts
Journal of Nuclear Medicine Dec 2020, jnumed.120.255679; DOI: 10.2967/jnumed.120.255679
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Selection of Single Domain Anti-Transferrin Receptor Antibodies for Blood-Brain Barrier Transcytosis Using a Neurotensin Based Assay and Histological Assessment of Target Engagement in a Mouse Model of Alzheimers Disease-Related Amyloid-Beta Pathology
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Clinical (Radionuclide Therapy)

  • Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
Show more Clinical (Radionuclide Therapy)

Similar Articles

Keywords

  • Oncology: Breast
  • Radioimmunoimaging
  • radionuclide therapy
  • Iodine-131
  • breast cancer
  • single domain antibody
  • theranostics
SNMMI

© 2025 SNMMI

Powered by HighWire